RNS Number : 5499A
Byotrol PLC
24 May 2023
 

Logo, company name Description automatically generated

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

EPA approval for

long-lasting performance against viruses

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to announce that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1).  This approval was received by the Company after close of business, on 22 May 2023. 

 

The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses.   This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). 

The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.

 David Traynor, Executive Director,  Byotrol plc comments:

 "This is fantastic news for Byotrol and confirms the excellence of our US surface sanitizers. 

Customers and consumers are now as concerned about protecting against viruses as well as bacteria.  This new approval means we can now make specific long-lasting efficacy claims against viruses, which should in turn significantly increase the commercial potential of our US formulations."

 

 

For further information contact:

 

Byotrol Plc


David Traynor, Executive Director

Dr Trevor Francis, Non- Executive Chairman

+44 (0)1925 742 000

Vivan Pinto, Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 




finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM






Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon                                          

 

byotrol@flagstaffcomms.com

 

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUSASROUUVUAR